Intra-Cellular Therapies Inc (ITCI)
73.04
-0.97
(-1.31%)
USD |
NASDAQ |
Apr 24, 16:00
73.04
0.00 (0.00%)
After-Hours: 20:00
Intra-Cellular Therapies Revenue (TTM): 462.18M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 462.18M |
September 30, 2023 | 418.10M |
June 30, 2023 | 364.16M |
March 31, 2023 | 309.11M |
December 31, 2022 | 249.13M |
September 30, 2022 | 187.22M |
June 30, 2022 | 136.95M |
March 31, 2022 | 100.88M |
December 31, 2021 | 81.71M |
September 30, 2021 | 68.60M |
June 30, 2021 | 54.36M |
March 31, 2021 | 37.23M |
December 31, 2020 | 22.53M |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 |
Date | Value |
---|---|
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 | 0.2458M |
September 30, 2017 | 0.3387M |
June 30, 2017 | 0.3123M |
March 31, 2017 | 0.426M |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | 0.2212M |
March 31, 2015 | 0.3831M |
December 31, 2014 | 0.5475M |
September 30, 2014 | 1.339M |
June 30, 2014 | 1.882M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
22.53M
Minimum
Dec 2020
462.18M
Maximum
Dec 2023
191.70M
Average
136.95M
Median
Jun 2022
Revenue (TTM) Benchmarks
Insmed Inc | 305.21M |
Fate Therapeutics Inc | 63.53M |
ADMA Biologics Inc | 258.22M |
Jaguar Health Inc | 9.761M |
Rhythm Pharmaceuticals Inc | 77.43M |